Michelle McMurray-Health
BIO CEO Dr. Michelle McMurry-Heath has stepped down amid reports of ongoing dissension within the group over its direction.

BIO CEO McMurry-Heath Steps Down Amid Reported Conflict with Board

Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence. BIO is the trade association and top lobbying group for the biotech industry, with a membership of over 1,000 companies of all sizes including drug manufacturers, some of which are also members of the brand name manufacturer trade group PhRMA.

The Wall Street Journal was first to report on McMurry-Heath’s leave, saying it took place “amid dissent within the organization about its direction and concern about its results,” according to anonymous sources. McMurry-Heath formally stepped down a day later, and has not commented publicly on her resignation. 

Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer